CLINICAL_TRIALS
trial_result
· 2009-09-15
Clinical Trial Update: Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age [Phase 3]
Summary
Phase 3 dose-ranging study of Atacand (candesartan) in hypertensive children aged 1 year to less than 6 years; results posted in 2009.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AstraZeneca | Conditions: Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2009-09-15